BCR-ABL mutation testing to predict response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia

Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myeloid leukemia (CML). Although randomized evidence demonstrates that imatinib (a commercially available TKI) prolongs event–free survival in patients with CML, some patients develop imatinib intolerance or resistance. I...

Descripción completa

Detalles Bibliográficos
Autores principales: Terasawa, Teruhiko, Dahabreh, Issa, Trikalinos, Thomas A
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Evidence on Genomic Tests
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3001986/
https://www.ncbi.nlm.nih.gov/pubmed/21188137
http://dx.doi.org/10.1371/currents.RRN1204

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3001986/
https://www.ncbi.nlm.nih.gov/pubmed/21188137
http://dx.doi.org/10.1371/currents.RRN1204

Ejemplares similares